GlassScriptPhysician profile
Katelyn H Rogers
NPI 1053877761
$5,370.76
in general payments reported to CMS, 2019-2025
33 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2022: $1,254 · 2023: $1,524 · 2024: $1,286 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,800 · Education: $16.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,800.45 |
| Education | $16.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,752.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $476.78 | 2024-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.69 | 2021-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $401.90 | 2021-2024 | Entyvio, Eohilia |
| Genzyme Corporation | $306.82 | 2023-2025 | |
| Novo Nordisk INC | $227.69 | 2024-2025 | Rybelsus, Ozempic |
| Ardelyx, INC. | $205.88 | 2023-2024 | Ibsrela |
| Amgen INC. | $170.64 | 2021-2025 | Repatha, Otezla, Avsola |
| Qol Medical, LLC | $137.04 | 2021-2024 | Sucraid, Sucraid |
| Lilly USA, LLC | $116.81 | 2023-2025 | Omvoh, Zepbound, Jardiance |
| Nestle Healthcare Nutrition INC. | $116.58 | 2022-2023 | |
| Pfizer INC. | $113.98 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $103.57 | 2022-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $102.19 | 2021 | |
| Celgene Corporation | $88.34 | 2023-2024 | Zeposia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $63.50 | 2022-2023 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $61.85 | 2023-2024 | Voquezna |
| Aimmune Therapeutics, INC. | $59.79 | 2024 | |
| Janssen Biotech, INC. | $53.61 | 2022-2023 | Stelara |
| Intercept Pharmaceuticals, INC. | $45.06 | 2023-2024 | Ocaliva |
| Ferring Pharmaceuticals INC. | $38.25 | 2023-2024 | Rebyota |
| Mylan Institutional INC. | $34.87 | 2023 | Hulio |
| Sandoz INC. | $32.96 | 2023 | Hyrimoz |
| Redhill Biopharma INC. | $32.74 | 2022 | |
| Glaxosmithkline, LLC. | $32.27 | 2025 | Trelegy Ellipta, Arexvy |
| Ironwood Pharmaceuticals, INC | $30.71 | 2021-2022 | |
| Tolmar, INC. | $28.99 | 2024-2025 | Jatenzo |
| Regeneron Healthcare Solutions, INC. | $23.77 | 2022 | |
| Exact Sciences Corporation | $20.62 | 2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $17.41 | 2022 | |
| Celltrion USA INC. | $16.10 | 2024 | Zymfentra |
| W. L. Gore & Associates, INC. | $14.55 | 2022 | |
| Intra-Sana Laboratories | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.